The International School of Metronomic chemotherapy (ISMe) founded by Marina Elena Cazzaniga, has the aim to improve the knowledge in this particular type of treatment, its characteristic mechanisms of action, the most recent results in different types of cancer, as well as contributing to scientific exchange among physicians, clinicians and basic researchers involved in this field.
By improving the skills of all health professionals dealing with cancer patients, ISMe helps shorten the time needed to transfer knowledge from research centres to daily practice.
Last but not least, is that the School has no charging fees.
In 2014, almost one and a third million people died from cancer in the EU-28, which equated to more than one quarter (26.4 %) of the total number of deaths. Cancer accounted for a somewhat higher share (29.7 %) of deaths among men than among women (23.2 %). Data EUROSTAT extracted in September 2017.
In 2018, 3.9 million new cases of cancer (all types, excluding non-melanoma skin cancer) and over 1.9 million cancer deaths are estimated in Europe. Lung, colon, female breast, pancreas and prostate cancers account for nearly half (49%) of all deaths due to cancer
57% of new cancer cases in 2012 occurred in less developed regions of the world that include Central America and parts of Africa and Asia; 65% of cancer deaths also occurred in these regions.
Approximately 38.4% of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2013–2015 data).
A recent comprehensive report of the advances in cancer field in the last decade shows that progress has been slow in terms of improved outcomes, quality of life, awareness and information regarding cancer disease. The level of evidence used to base many recommendations remains low, and more and better designed trials are needed to address clinically important questions in different areas of cancer care.
Every advanced cancer patient must have access to optimal cancer treatment and supportive care according to the highest standards of patient-centred care, as defined by:
– Open communication between patients and their cancer care teams as a primary goal.
– Educating patients about treatment options and supportive care, through development and dissemination of evidence-based information in a clear, culturally appropriate form.
– Encouraging patients to be proactive in their care and to share decision-making with their health care providers.
– Empowering patients to develop the capability of improving their own quality of life within their cancer experience.
– Always considering patient preferences, values and needs as essential to optimal cancer care [Cardoso F, 2018].
Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged drug-free breaks that leads to antitumor activity [Cazzaniga ME, 2017]. A great number of Phase II studies have been published starting from mid-2000s, showing an increasing interest of clinicians on this topic. The results of these studies showed that this strategy is not only effective but has a low toxicity profile too, proposing as a promising strategy for some cancer patients.
Devoted to patients - Devoted to Knowledge
ISMe’s mission is reflected in its motto “Devoted to patients – Devoted to Knowledge”, which emphasizes on one side the willingness to be close to cancer patients, their needs and their expectations in terms of new possibilities of cure, on the other side the importance of rapidly sharing among colleagues the new results of this treatment protocol.
ISMe’s aim is also to pay particular attention on the development of easy and affordable ways to the transfer of knowledge in geographical areas that are least supported by pharmaceutical companies as well as in Countries and regions with limited economical resources.
As an independent, non-profit organisation which has the mission to improve the knowledge about clinical results and patient opportunities, ISMe is committed to working with all stakeholder groups trying to improve treatment opportunities.
The School recognises that different industries make an important contribution to improve cancer outcomes, through a cultural exchange web-based program. For this reason, ISMe fosters on-going dialogue and collaboration with industry partners, by maintaining at the same time a complete independency from them.
The School maintains total editorial control over the planning and execution of all EUmCHT projects. Partners may be invited to contribute with ideas, as appropriate, but decisions about procedures and content are made by the Faculty.
The current industry partner supports the International School of Metronomic Chemotherapy (ISME),meetings and educational initiatives, in line with ISME’s mission to develop knowledge on metronomic chemotherapy.
Do not hesitate to contact the ISME Administration or School Manager for more information about sponsorship opportunities.
ISME is supported through an unrestricted educational grant from Pierre Fabre Pharma
Department of Hematology & Pediatric Oncology, Hôpital pour Enfants de La Timone, AP-HM and head of the SMARTC CRO2- (Centre de Recherche en Cancérologie de Marseille)
Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Italy.
Preclinical translational research, Sunnybrook Health Sciences Centre Toronto,
Division of Medical Senology, European Institute of Oncology, Milan, Italy.
Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
Jagiellonian University – Medical College Hospital, Cracow, Poland
South East Asian Faculty Members